Currently, some anti-IL-17A (secukinumab, ixekizumab, bimekizumab, brodalumab, etc.)and anti-IL-23A (ustekinumab) monoclonal antibodies are used for the treatment of different autoimmune disorders including IBD, ulcerative colitis, psoriasis arthritis, rheumatoid arthritis, etc.52,53. This evidence concerns the gene IL17A and rheumatoid arthritis.